Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

Annals of Internal Medicine

Volumn 138, Issue 2, 2003, Pages 98-104

  Tonelli, Marcello ^a   Moyé, Lemuel ^b   Sacks, Frank M ^b   Kiberd, Bryce ^b   Curhan, Gary ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SKIN CANCER; SUICIDE ATTEMPT; TREATMENT OUTCOME;

EID: 0037458229     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-2-200301210-00010     Document Type: Article

References (22)

1. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 1998;32:992-9. [PMID: 9856515]
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-9, [PMID: 9820470]
3. Rostand SG. Coronary heart disease in chronic renal insufficiency: some management considerations. J Am Soc Nephrol. 2000;11:1948-56. [PMID: 11004228]
4. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356:147-52. [PMID: 10963260]
5. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35:S117-31. [PMID: 10766010]
6. Kitiyakara C, Gonin J, Massy Z, Wilcox CS. Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens. 2000;9:477-87, [PMID: 10990365]
7. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis. 2000;36:S24-30. [PMID: 11118155]
8. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13:180-93. [PMID: 2490833]
9. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36. [PMID: 11304102]
10. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12:218-25. [PMID: 11158211]
11. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484-9. [PMID: 11228171]
12. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-34. [PMID: 10401026]
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. [PMID: 7968073]
14. Sacks FM, Pfeffer MA, Moyé L, Brown LE, Hamm P, Cole TG, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol. 1991;68:1436-46. [PMID: 1746424]
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. [PMID: 1244564]
16. NKF-K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis. 2002;39(2 Suppl 1):S76-S110.
17. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93-8. [PMID: 2046134]
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9. [PMID: 8801446]
19. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-9. [PMID: 10594797]
20. Sarnak MJ, Levey AS. Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J Thromb Thrombolysis. 2000;10:169-80. [PMID: 11005939]
21. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001;55:39-44. [PMID: 11200866]
22. Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol. 1992;32:124-32. [PMID: 1613121]